Antibody-mediated rejection assays, therapeutics, and monitoring tools have become critical for early detection and treatment of organ rejection events. Products such as complement inhibitors, anti-CD20 monoclonal antibodies, and novel biosensors offer improved graft survival, lower hospital readmission rates, and enhanced patient quality of life. These immunomodulatory therapies and diagnostic kits meet the urgent need for precise risk stratification and tailored interventions in transplant centers. Antibody-mediated Rejection Market include rapid turnaround time, high sensitivity and specificity, and seamless integration with electronic health records to support clinical decision-making. Rising healthcare expenditure on transplantation, coupled with advances in immunodiagnostics and biologics manufacturing, is creating numerous market opportunities. Continued investment in research and development fosters product innovation, addressing current market challenges such as late-stage rejection detection and high therapy costs. The integration of digital pathology and AI-driven analysis is reshaping market dynamics, enabling predictive insights into antibody-mediated rejection events. This convergence of technology and therapeutics underscores the growing market share of cutting-edge solutions.

The antibody-mediated rejection market is estimated to be valued at USD 142.7 Mn in 2025 and is expected to reach USD 331.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Key Takeaways

Key players operating in the Antibody-mediated Rejection Market are

·         CSL Behring,

·         Hansa Biopharma

·         AB,

·         Viela Bio,

·         Janssen Biotech

·         Pfizer.

These market players drive competition through strategic partnerships, mergers and acquisitions, and robust R&D initiatives. CSL Behring advances complement inhibitor programs, Hansa Biopharma focuses on novel salvage therapies, and Viela Bio develops targeted monoclonal antibodies. Janssen Biotech and Pfizer bolster diagnostic assay portfolios to shape future market share and strengthen their foothold in transplant immunology.

Get More Insight On : Antibody-mediated Rejection Market

Get this Report in Japanese Language: 抗体介在性拒絶反応市場

Get this Report in Korean Language: 항체매개거부시장